New drug aims to tame dual threat for dialysis patients
NCT ID NCT00542386
Summary
This large, completed Phase 3 trial tested whether the drug MCI-196 could help control two common problems in people with kidney failure on dialysis: high phosphorus and high 'bad' cholesterol. The study involved 642 stable dialysis patients who were randomly assigned to receive either the drug or a placebo for 12 weeks. The main goals were to see if the drug safely lowered blood phosphorus and LDL cholesterol levels compared to the dummy pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Ajka, Hungary
-
Study site
Baja, Hungary
-
Study site
Budapest, Hungary
-
Study site
Esztergom, Hungary
-
Study site
Győr, Hungary
-
Study site
Hatvan, Hungary
-
Study site
Kisvárda, Hungary
-
Study site
Lecco, Italy
-
Study site
Modena, Italy
-
Study site
Pavia, Italy
-
Study site
Roma, Italy
-
Study site
Alor Star, Malaysia
-
Study site
Ipoh, Malaysia
-
Study site
Kajang, Malaysia
-
Study site
Klang, Malaysia
-
Study site
Kota Kinabalu, Malaysia
-
Study site
Kuala Terengganu, Malaysia
-
Study site
Kuantan, Malaysia
-
Study site
Kuching, Malaysia
-
Study site
Malacca, Malaysia
-
Study site
Seremban, Malaysia
-
Study site
Taiping, Malaysia
-
Study site
Skopje, North Macedonia
-
Study site
Lodz, Poland
-
Study site
Poznan, Poland
-
Study site
Płock, Poland
-
Study site
Rybnik, Poland
-
Study site
Warsaw, Poland
-
Study site
Wroclaw, Poland
-
Study site
Zielona Góra, Poland
-
Study site
Arkhangelsk, Russia
-
Study site
Armavir, Russia
-
Study site
Chelyabinsk, Russia
-
Study site
Chita, Russia
-
Study site
Irkutsk, Russia
-
Study site
Ivanovo, Russia
-
Study site
Kaluga, Russia
-
Study site
Kemerovo, Russia
-
Study site
Khabarovsk, Russia
-
Study site
Krasnodar, Russia
-
Study site
Krasnoyarsk, Russia
-
Study site
Moscow, Russia
-
Study site
Nizhny Novgorod, Russia
-
Study site
Novokuznetsk, Russia
-
Study site
Novorossiysk, Russia
-
Study site
Novosibirsk, Russia
-
Study site
Omsk, Russia
-
Study site
Petrozavodsk, Russia
-
Study site
Rostov-on-Don, Russia
-
Study site
Saint Petersburg, Russia
-
Study site
Smolensk, Russia
-
Study site
Tomsk, Russia
-
Study site
Tver', Russia
-
Study site
Tyumen, Russia
-
Study site
Vladimir, Russia
-
Study site
Vladivostok, Russia
-
Study site
Volzhskiy, Russia
-
Study site
Yaroslavl, Russia
-
Study site
Yekaterinburg, Russia
-
Study site
Belgrade, Serbia
-
Study site
Kragujevac, Serbia
-
Study site
Niš, Serbia
-
Study site
Novi Sad, Serbia
-
Study site
Chernivtsi, Ukraine
-
Study site
Dnipro, Ukraine
-
Study site
Ivano-Frankivsk, Ukraine
-
Study site
Kharkiv, Ukraine
-
Study site
Kiev, Ukraine
-
Study site
Mykolaiv, Ukraine
-
Study site
Ternopil, Ukraine
-
Study site
Uzhhorod, Ukraine
-
Study site
Zaporizhya, Ukraine
-
Study site
Zhytomyr, Ukraine
Conditions
Explore the condition pages connected to this study.